Skip to main content
SpringerLink
Log in

Budget impact of infliximab biosimilars varies

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. International Society for Pharmacoeconomics and Outcomes Research

Reference

  • Bocquet F, et al. Budget Impact Analysis of Implementing Tenders Between the Branded Infliximab and its Biosimilars in the Public Hospitals of Paris. 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PMS30, 7 Nov 2015. Available from: URL: http://www.ispor.org/research_study_digest/list.asp?qs=43169

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Budget impact of infliximab biosimilars varies. PharmacoEcon Outcomes News 742, 17 (2015). https://doi.org/10.1007/s40274-015-2645-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2645-1

Search

Navigation